These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18061317)

  • 21. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate.
    Zeng W; Tan AC; Horrocks K; Jackson DC
    Vaccine; 2015 Jul; 33(30):3526-32. PubMed ID: 26049002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-assembly polymerization enhances the immunogenicity of influenza M2e peptide.
    Zou P; Li Y; Huang J; Wu F
    Microbes Infect; 2017 Dec; 19(12):648-654. PubMed ID: 28939356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
    Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.
    Tao W; Gill HS
    Vaccine; 2015 May; 33(20):2307-15. PubMed ID: 25842219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
    De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
    Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin.
    Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z
    Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
    Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
    Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge.
    Kaminaka K; Matsuda J; Nozaki C
    Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
    Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.
    Zhou C; Zhou L; Chen YH
    Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.
    Deng L; Ibañez LI; Van den Bossche V; Roose K; Youssef SA; de Bruin A; Fiers W; Saelens X
    PLoS One; 2015; 10(5):e0126650. PubMed ID: 25973787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.
    Wang W; Huang B; Jiang T; Wang X; Qi X; Gao Y; Tan W; Ruan L
    PLoS One; 2012; 7(12):e52488. PubMed ID: 23285063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens.
    Elaish M; Kang KI; Xia M; Ali A; Shany SA; Wang L; Jiang X; Lee CW
    Vaccine; 2015 Sep; 33(38):4901-9. PubMed ID: 26232342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.
    Zou P; Liu W; Chen YH
    Int Immunopharmacol; 2005 Apr; 5(4):631-5. PubMed ID: 15710332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.